Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients primary care records in situ using OpenSAFELY

Conclusion and implications We observed a spike in antipsychotic prescribing in the dementia and care home groups, which correlated with lockdowns and was likely due to prescribing of antipsychotics for palliative care. We observed gradual increases in antipsychotic use in dementia and care home patients and decreases in their use in patients with learning disability or autism.

http://mentalhealth.bmj.com/cgi/content/short/26/1/e300775?rss=1

Source: Evidence-Based Mental Health - September 15, 2023 Category: Psychiatry & Psychology Authors: Macdonald, O., Green, A., Walker, A., Curtis, H., Croker, R., Brown, A., Butler-Cole, B., Andrews, C., Massey, J., Inglesby, P., Morton, C., Fisher, L., Morley, J., Mehrkar, A., Bacon, S., Davy, S., Evans, D., Dillingham, I., Ward, T., Hulme, W., Bates, C Tags: Open access, COVID-19 Pharmacological treatments Source Type: research